Business
Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer
Highlights Broad Development Potential of Proprietary Portfolio Targeting FABPsSOLANA BEACH, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, announces the publication of a peer-reviewed article, “The Emerging Role of Fatty Acid Binding Protein 3 (FABP3) in Cancers”, in Drug
About this update from Artelo Biosciences, Inc.
[{"type":"image","alt":"Artelo Biosciences","displaySize":"","headline":null,"caption":"Artelo Biosciences","className":"","disableSlideshowImg":false,"size":{"original":{"width":183,"height":80,"url":"https://media.zenfs.com/en/globenewswire.com/0fcfe43e16f7cfc8e2a0ef70f1c6364e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dtRWcM_YXYcz7bexobLzxA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTE1NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0fcfe43e16f7cfc8e2a0ef70f1c6364e","width":183,"height":80}},"lazy":false},{"type":"text","content":"Highlights Broad Development Potential of Proprietary Portfolio Targeting FABPs","length":79,"tagName":"p"},{"type":"text","content":"SOLANA BEACH, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, announces the publication of a peer-reviewed article, “The Emerging Role of Fatty Acid Binding Protein 3 (FABP3) in Cancers”, in Drug Discovery Today. The publication’s lead author is Dr. George Warren, Principal Scientist at Artelo. This publication marks the third in a trilogy of reviews exploring the protumoral roles of FABP isoforms 3, 5, and 7 in cancer biology.","length":656,"tagName":"p"},{"type":"text","content":"This publication underscores growing evidence that FABP3, similar to FABP5 and FABP7, plays a significant role in cancer progression across multiple tumor types. FABP3 promotes tumorigenic processes through mechanisms linked to lipid metabolism, hypoxia, and ferroptosis—pathways increasingly recognized as critical to cancer cell survival and proliferation. Importantly, both genetic and pharmacological inhibition of FABP3 demonstrated therapeutic benefits in preclinical cancer models.","length":488,"tagName":"p"},{"type":"text","content":"“This review adds further depth to our understanding of how different FABP isoforms affect cancer,” said Dr. George Warren. “Consistent with our previous reviews on the role of FABP5 and FABP7 in cancer, FABP3 also shows oncogenic effects in a wide range of tumor types. This research highlights the dysregulation of lipid metabolism in cancer and represents a unique opportunity to target FABP isoforms dependent on cancer type.”","length":430,"tagName"...